Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using AI in Anticancer and Regenerative Medicine
Oncocross, a Seoul-based artificial intelligence (AI) drug discovery and development biotech startup, has signed a joint research agreement with JW Pharmaceutical to develop new drugs based on the AI platform.
Oncocross has completed the Phase I global clinical trial of OC514 in Australia for the treatment of sarcopenia and other rare muscular diseases.
SEOUL, South Korea--(BUSINESS WIRE)--Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular diseases. Phase 1 was conducted in Australia.